



GUJARAT THEMIS BIOSYN LIMITED

REGD. OFFICE & FACTORY : 69/C, GIDC, INDUSTRIAL ESTATE,
VAPI - 396 195. DIST. VALSAD, GUJARAT, INDIA.
TEL : 0260-2430027
Email : hrm@gtbl.in.net
CIN No.: L24230GJ1981PLC004878

To,
Rakesh Parekh
Special Assistant
Listing Compliance
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai- 400001
Email: corp.relations@bseindia.com

Date: 26th July, 2021

Dear Sirs,

Sub: Revised Disclosure of Inter-se Transfer of Shares between the Promoters/ Promoters Group in accordance with Regulation 10(5) of SEBI (SAST) Regulations, 2011.

We refer to your email dated 26th July, 2021 asking for the revised rectify disclosure under regulation 10(5) of Securities and Exchange Board of India {Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

In this connection, we have received revised rectified disclosure under regulation 10(5) of Securities and Exchange Board of India {Substantial Acquisition of Shares and Takeovers) Regulations, 2011 from Pharmaceutical Business Group (India) Limited (Acquirer).

We are forwarding herewith the same.

Please take the same on record.

Thanking you,

Yours faithfully,
For Gujarat Themis Biosyn Limited

Rahul Soni
Company Secretary



REGD. OFFICE: "11/12 UDYOG NAGAR, S.V. ROAD, GOREGAON (WEST), MUMBAI-400 104."
TEL: 91-22 6760 7080; FAX: 91-22 6760 7070, EMAIL: raveendran@themismedicare.com

CIN:U24239MH1991IPLC059995

To,
Rakesh Parekh
Special Assistant
Listing Compliance
BSE Ltd.
P J Towers, Dalal Street,
Mumbai - 400001, India.
Email: corp.relations@bseindia.com

Dear Sirs,

Sub: Revised Disclosure of Inter-se Transfer of Shares between the Promoters/ Promoters Group in accordance with Regulation 10(5) of SEBI (SAST) Regulations, 2011.


With reference to your email dated 26th July, 2021 asking for the revised rectify disclosure under regulation 10(5) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Please take the same on record the revised rectified disclosure under regulation 10(5) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

CC to;
Company: secretary@gtbl.in.net

Thanking you,

Yours faithfully,
For Pharmaceutical Business Group (India) Limited




Kersasp Kalianwala
Director



Revised Disclosure under regulation 10 (5)

1	Name of the Target Company	Gujarat Themis Biosyn Limited
2	Name of the Acquirer	Pharmaceutical Business Group (India) Limited
3	Whether the acquirer(s) is/ are promoters of the TC prior to the transaction. If not, nature of relationship or association with the TC or its promoters	Yes. Pharmaceutical Business Group (India) Limited is one of the promoters of the Target Company. Not applicable
4	Details of the proposed acquisition a. Name of the person(s) from whom shares are acquired b. Proposed date of Acquisition c. Number of shares to be acquired from each person mentioned in 4 (a) above d. Total shares to be acquired as % of share capital of TC . e. Price at which shares are proposed to be acquired f. Rationale, if any, for the proposed transfer	Yuhan Corporation On or after July 30, 2021 38,50,000 (26.50 %) Rs. 150/- per share Inter-se transfer of shares amongst promoters of the Company, as per the mutual agreement between the promoters.



Revised Disclosure under regulation 10 (5)

5	Relevant sub-clause of regulation 10(1)(a) under which the acquirer is exempted from making open offer	Regulation 10(1)(a)(ii) of SEBI (SAST) Regulation, 2011
6	If, frequently traded, volume weighted average market price for a period of 60 trading days preceding the date of issuance of this notice as traded on BSE Ltd, the stock exchange where the maximum volume of trading in the shares of the TC are recorded during such period.	Rs. 310.64 Per share
7	If in-frequently traded, the price as determined in terms of clause (e) of sub-regulation (2) of regulation 8.	Not applicable
8	Declaration by the acquirer, that the acquisition price would not be higher by more than 25% of the price computed in point 6 or point 7 as applicable.	The Acquirer hereby declares that the acquisition price shall not be higher than 25% of the price mentioned in (6) above. -
9	Declaration by the acquirer, that the transferor and transferee have complied / will comply with applicable disclosure requirements in Chapter V of the Takeover Regulations, 2011 (corresponding provisions of the repealed Takeover Regulations 1997)	Yes, the Acquirer hereby declares that the transferor and transferee have complied with applicable disclosure requirement in Chapter V of the Takeover Regulation, 2011
10	Declaration by the acquirer that all the conditions specified under regulation 10(1)(a) with respect to exemptions has been duly complied with	The Acquirer hereby declares that all the conditions specified under regulation 10 (1) (a) with respect to exemption has been complied with.



Revised Disclosure under regulation 10 (5)

11	Shareholding Details	Before the proposed Transaction		After the proposed transaction	
		No of Shares/voting rights	% w.r.t total share capital of TC	No of Shares/voting rights	% w.r.t total share capital of TC
	a. Acquirer(s) and PACs (other than sellers) - Pharmaceutical Business Group(India) Limited				
1.	Pharmaceutical Business Group [India] Ltd	35,82,000	24.65	74,32,000	51.15
2.	Themis Medicare Limited	33,69,605	23.19	33,69,605	23.19
3.	Jayshree D Patel	70,645	0.49	70,645	0.49
4.	Sachin Dinesh Patel	7,100	0.05	7,100	0.05
5.	Reena S Patel	5,600	0.04	5,600	0.04
6.	Dinesh Shantilal Patel	4,701	0.03	4,701	0.03
7.	Anay Rupen Choksi	3,047	0.02	3,047	0.02
8.	Nysha Rupen Choksi	3,047	0.02	3,047	0.02
	Total	70,45,745	48.49%	1,08,95,745	74.99%
	b. Seller (s) Yuhan Corporation	38,50,000	26.50%	NIL	NIL

For Pharmaceutical Business Group (India) Limited

Kersasp Kalianwala

Kersasp Kalianwala

Director

Place: Mumbai

Date: July 26, 2021



REGD. OFFICE: "11/12 UDYOG NAGAR, S.V. ROAD, GOREGAON (WEST), MUMBAI-400 104."
TEL: 91-22 6760 7080; FAX: 91-22 6760 7070, EMAIL: raveendran@themismedicare.com

CIN:U24239MH1991IPLC059995

DECLARATION BY PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED (THE ACQUIRER) Regulation
10(5)

The Acquirer hereby declares that the acquisition price shall not be higher than 25% of the price mentioned in (6) above.

The Acquirer hereby declares that the transferor and transferee have complied with applicable disclosure requirement in Chapter V of the Takeover Regulations, 2011.

The Acquirer hereby declares that all the conditions specified under regulation 10 (1) (a) with respect to exemption has been complied with.

For PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED



Kersasp Kalianwala
Director

